Net Income (Loss) Attributable to Parent in USD of Nascent Biotech Inc. from Q4 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nascent Biotech Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q4 2013 to Q2 2024.
  • Nascent Biotech Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2024 was -$377,390.000, a 30.1% increase year-over-year.
  • Nascent Biotech Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Jun 2024 was -$1,924,848.000, a 5.71% increase year-over-year.
  • Nascent Biotech Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$2,087,682.000, a 25.5% increase from 2022.
  • Nascent Biotech Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$2,800,969.000, a 495% decline from 2021.
  • Nascent Biotech Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$470,390.000, a 50.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Nascent Biotech Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$1,924,848 -$377,390 +$162,834 +30.1% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 -$2,087,682 -$512,576 +$5,483 +1.1% 01 Jan 2024 31 Mar 2024 10-K 01 Jul 2024
Q4 2023 -$2,093,165 -$205,406 +$631,914 +75.5% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 -$2,725,079 -$829,476 -$683,762 -4.7% 01 Jul 2023 30 Sep 2023 10-Q 14 Feb 2024
Q2 2023 -$2,041,317 -$540,224 +$759,652 +58.4% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$2,800,969 -$518,059 -$111,452 -27.4% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 -$2,689,517 -$837,320 -$1,434,643 -2.4% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 -$1,254,874 -$145,714 +$65,316 +31% 01 Jul 2022 30 Sep 2022 10-Q 14 Feb 2024
Q2 2022 -$1,320,190 -$1,299,876 -$849,800 -1.9% 01 Apr 2022 30 Jun 2022 10-Q 14 Feb 2024
Q1 2022 -$470,390 -$406,607 -$789,612 -2.1% 01 Jan 2022 31 Mar 2022 10-K/A 03 Jul 2023
Q4 2021 $319,222 $597,323 +$1,316,830 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 -$997,608 -$211,030 +$207,264 +49.6% 01 Jul 2021 30 Sep 2021 10-Q 14 Feb 2023
Q2 2021 -$1,204,872 -$450,076 -$246,105 -1.2% 01 Apr 2021 30 Jun 2021 10-Q 14 Feb 2023
Q1 2021 -$958,767 $383,005 +$3,411,412 01 Jan 2021 31 Mar 2021 10-K 15 Jun 2022
Q4 2020 -$4,370,179 -$719,507 -$349,355 -94.4% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 -$4,020,824 -$418,294 -$86,438 -26% 01 Jul 2020 30 Sep 2020 10-Q 14 Feb 2022
Q2 2020 -$3,934,386 -$203,971 +$69,767 +25.5% 01 Apr 2020 30 Jun 2020 10-Q 14 Feb 2022
Q1 2020 -$4,004,153 -$3,028,407 -$2,693,782 -8.1% 01 Jan 2020 31 Mar 2020 10-K 08 Jul 2021
Q4 2019 -$1,310,371 -$370,152 -$113,587 -44.3% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021
Q3 2019 -$1,196,784 -$331,856 +$6,142 +1.8% 01 Jul 2019 30 Sep 2019 10-Q 09 Feb 2021
Q2 2019 -$1,202,926 -$273,738 +$165,981 +37.7% 01 Apr 2019 30 Jun 2019 10-Q 09 Feb 2021
Q1 2019 -$1,368,907 -$334,625 +$466,670 +58.2% 01 Jan 2019 31 Mar 2019 10-K 22 Jun 2020
Q4 2018 -$1,835,577 -$256,565 +$307,057 +54.5% 01 Oct 2018 31 Dec 2018 10-Q 11 Feb 2020
Q3 2018 -$2,142,634 -$337,998 +$220,200 +39.4% 01 Jul 2018 30 Sep 2018 10-Q 18 Nov 2019
Q2 2018 -$2,362,834 -$439,719 -$141,535 -47.5% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019
Q1 2018 -$2,221,299 -$801,295 -$337,450 -72.8% 01 Jan 2018 31 Mar 2018 10-K 12 Jul 2019
Q4 2017 -$1,883,849 -$563,622 +$4,193 +0.74% 01 Oct 2017 31 Dec 2017 10-Q 13 Feb 2019
Q3 2017 -$1,888,042 -$558,198 -$2,053,823 -1.4% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018
Q2 2017 $165,781 -$298,184 -$971,156 -1.4% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018
Q1 2017 $1,136,937 -$463,845 +$280,627 +37.7% 01 Jan 2017 31 Mar 2017 10-K 29 Jun 2018
Q4 2016 $856,310 -$567,815 -$228,590 -67.4% 01 Oct 2016 31 Dec 2016 10-Q 31 Jan 2018
Q3 2016 $1,084,900 $1,495,625 +$3,764,175 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2017
Q2 2016 -$2,679,275 $672,972 +$1,469,465 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 -$4,148,740 -$744,472 +$192,141 +20.5% 01 Jan 2016 31 Mar 2016 10-K 29 Jun 2017
Q4 2015 -$4,340,881 -$339,225 +$316,125 +48.2% 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017
Q3 2015 -$4,657,006 -$2,268,550 -$1,940,293 -5.9% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 -$2,716,713 -$796,493 -$564,584 -2.4% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 -$2,152,129 -$936,613 01 Jan 2015 31 Mar 2015 10-K 14 Jul 2016
Q4 2014 -$655,350 +$748,572 +53.3% 01 Oct 2014 31 Dec 2014 10-Q 19 Feb 2016
Q3 2014 -$328,257 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015
Q2 2014 -$231,909 01 Apr 2014 30 Jun 2014 10-Q 30 Jul 2015
Q4 2013 -$1,403,922 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015

Nascent Biotech Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$2,087,682 +$713,287 +25.5% 01 Apr 2023 31 Mar 2024 10-K 01 Jul 2024
2022 -$2,800,969 -$2,330,579 -5% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 -$470,390 +$488,377 +50.9% 01 Apr 2021 31 Mar 2022 10-K/A 03 Jul 2023
2020 -$958,767 +$3,045,386 +76.1% 01 Apr 2020 31 Mar 2021 10-K 15 Jun 2022
2019 -$4,004,153 -$2,635,246 -1.9% 01 Apr 2019 31 Mar 2020 10-K 08 Jul 2021
2018 -$1,368,907 +$852,392 +38.4% 01 Apr 2018 31 Mar 2019 10-K 22 Jun 2020
2017 -$2,221,299 -$3,358,236 -3% 01 Apr 2017 31 Mar 2018 10-K 12 Jul 2019
2016 $1,136,937 +$5,285,677 01 Apr 2016 31 Mar 2017 10-K 29 Jun 2018
2015 -$4,148,740 -$1,996,611 -92.8% 01 Apr 2015 31 Mar 2016 10-K 29 Jun 2017
2014 -$2,152,129 -$234,277 -12.2% 01 Apr 2014 31 Mar 2015 10-K 14 Jul 2016
2013 -$1,917,852 01 Apr 2013 31 Mar 2014 10-K 02 Jul 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.